Orally Administered Lenalidomide (CC-5013) Is Anti-angiogenic In ...
The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search: Search Advanced Clipboard Save Email Send to- Clipboard
- My Bibliography
- Collections
- Citation manager
Save citation to file
Format: Summary (text) PubMed PMID Abstract (text) CSV Create file CancelEmail citation
Subject: 1 selected item: 15797261 - PubMed To: From: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email CancelAdd to Collections
- Create a new collection
- Add to an existing collection
Add to My Bibliography
- My Bibliography
Your saved search
Name of saved search: Search terms: Test search terms Would you like email updates of new search results? Saved Search Alert Radio Buttons- Yes
- No
Create a file for external citation management software
Create file CancelYour RSS Feed
Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link CopyFull text links
Elsevier Science Full text linksActions
CiteCollectionsAdd to Collections- Create a new collection
- Add to an existing collection
Share
- Permalink Copy
Page navigation
- Title & authors
- Abstract
- Similar articles
- Cited by
- Publication types
- MeSH terms
- Substances
- Related information
- LinkOut - more resources
Abstract
The thalidomide analogue and immunomodulatory drug (IMiD) lenalidomide (CC-5013, REVLIMID) is emerging as a useful treatment for a number of cancers and has recently entered phase III trials for multiple myeloma. It has been suggested that the anti-tumor effect of lenalidomide is related to its anti-angiogenic potency. In this regard, we have previously shown that lenalidomide inhibits angiogenesis in both rat and human in vitro models but does not affect endothelial cell proliferation. We now show that oral administration of lenalidomide attenuates growth factor-induced angiogenesis in vivo; the rat mesenteric window assay was utilized to show that lenalidomide significantly inhibits vascularization in a dose-dependent manner. We also found that lenalidomide significantly inhibits growth factor-induced endothelial cell migration. This correlates with the inhibitory effect of lenalidomide on growth factor-induced Akt phosphorylation, thereby providing a potential mechanism for its anti-migratory and subsequent anti-angiogenic effects. These data further support the use of lenalidomide as an orally administered drug for the effective treatment of angiogenesis-dependent conditions, including cancer, and suggest a potential mechanism of action.
PubMed Disclaimer
Similar articles
- The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Lu L, Payvandi F, Wu L, Zhang LH, Hariri RJ, Man HW, Chen RS, Muller GW, Hughes CC, Stirling DI, Schafer PH, Bartlett JB. Lu L, et al. Microvasc Res. 2009 Mar;77(2):78-86. doi: 10.1016/j.mvr.2008.08.003. Epub 2008 Sep 4. Microvasc Res. 2009. PMID: 18805433
- Pseudolarix acid B inhibits angiogenesis by antagonizing the vascular endothelial growth factor-mediated anti-apoptotic effect. Tan WF, Zhang XW, Li MH, Yue JM, Chen Y, Lin LP, Ding J. Tan WF, et al. Eur J Pharmacol. 2004 Sep 24;499(3):219-28. doi: 10.1016/j.ejphar.2004.07.063. Eur J Pharmacol. 2004. PMID: 15381043
- Ruboxistaurin, a PKCbeta inhibitor, inhibits retinal neovascularization via suppression of phosphorylation of ERK1/2 and Akt. Nakamura S, Chikaraishi Y, Tsuruma K, Shimazawa M, Hara H. Nakamura S, et al. Exp Eye Res. 2010 Jan;90(1):137-45. doi: 10.1016/j.exer.2009.09.022. Epub 2009 Oct 13. Exp Eye Res. 2010. PMID: 19825373
- Properties of thalidomide and its analogues: implications for anticancer therapy. Teo SK. Teo SK. AAPS J. 2005 Mar 22;7(1):E14-9. doi: 10.1208/aapsj070103. AAPS J. 2005. PMID: 16146335 Free PMC article. Review.
- Lenalidomide in solid tumors. Segler A, Tsimberidou AM. Segler A, et al. Cancer Chemother Pharmacol. 2012 Jun;69(6):1393-406. doi: 10.1007/s00280-012-1874-2. Epub 2012 May 15. Cancer Chemother Pharmacol. 2012. PMID: 22584909 Review.
Cited by
- Pathophysiology in Brain Arteriovenous Malformations: Focus on Endothelial Dysfunctions and Endothelial-to-Mesenchymal Transition. Jeong JY, Bafor AE, Freeman BH, Chen PR, Park ES, Kim E. Jeong JY, et al. Biomedicines. 2024 Aug 7;12(8):1795. doi: 10.3390/biomedicines12081795. Biomedicines. 2024. PMID: 39200259 Free PMC article. Review.
- Defining the Role of Oral Pathway Inhibitors as Targeted Therapeutics in Arteriovenous Malformation Care. Mansur A, Radovanovic I. Mansur A, et al. Biomedicines. 2024 Jun 11;12(6):1289. doi: 10.3390/biomedicines12061289. Biomedicines. 2024. PMID: 38927496 Free PMC article. Review.
- Molecular and Structural Characterization of Lenalidomide-Mediated Sequestration of eIF3i. Lin Z, Shen D, Yang B, Woo CM. Lin Z, et al. ACS Chem Biol. 2022 Nov 18;17(11):3229-3237. doi: 10.1021/acschembio.2c00706. Epub 2022 Nov 3. ACS Chem Biol. 2022. PMID: 36325969 Free PMC article.
- Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms. Guo H, Yang J, Wang H, Liu X, Liu Y, Zhou K. Guo H, et al. Front Immunol. 2022 Oct 12;13:1017990. doi: 10.3389/fimmu.2022.1017990. eCollection 2022. Front Immunol. 2022. PMID: 36311747 Free PMC article. Review.
- Treatment Options for Recurrent Primary CNS Lymphoma. Kaulen LD, Baehring JM. Kaulen LD, et al. Curr Treat Options Oncol. 2022 Nov;23(11):1548-1565. doi: 10.1007/s11864-022-01016-5. Epub 2022 Oct 7. Curr Treat Options Oncol. 2022. PMID: 36205806 Review.
Publication types
- Research Support, Non-U.S. Gov't Actions
- Search in PubMed
- Search in MeSH
- Add to Search
MeSH terms
- Administration, Oral Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Angiogenesis Inhibitors / pharmacology* Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Animals Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Area Under Curve Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Cell Movement / drug effects* Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Dose-Response Relationship, Drug Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Endothelium, Vascular / cytology Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Endothelium, Vascular / drug effects* Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Humans Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Kinetics Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Lenalidomide Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Male Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Mesentery / blood supply Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Mesentery / cytology Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Phosphorylation / drug effects Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Protein Serine-Threonine Kinases / metabolism* Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Proto-Oncogene Proteins / metabolism* Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Proto-Oncogene Proteins c-akt Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Rats Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Rats, Sprague-Dawley Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Thalidomide / administration & dosage* Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Thalidomide / analogs & derivatives* Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Thalidomide / pharmacokinetics Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Thalidomide / pharmacology* Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Umbilical Veins / cytology Actions
- Search in PubMed
- Search in MeSH
- Add to Search
Substances
- Angiogenesis Inhibitors Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Proto-Oncogene Proteins Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Thalidomide Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- AKT1 protein, human Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Akt1 protein, rat Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Protein Serine-Threonine Kinases Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Proto-Oncogene Proteins c-akt Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Lenalidomide Actions
- Search in PubMed
- Search in MeSH
- Add to Search
Related information
- PubChem Compound
- PubChem Compound (MeSH Keyword)
- PubChem Substance
LinkOut - more resources
Full Text Sources
- Elsevier Science
Other Literature Sources
- The Lens - Patent Citations Database
Miscellaneous
- NCI CPTAC Assay Portal
- Clipboard
- Save
- My Bibliography
- Collections
- Citation Manager
NCBI Literature Resources
MeSH PMC Bookshelf Disclaimer
The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.
Từ khóa » Cc-5013
-
Efficacy Of CC-5013 (Revlimid Or Lenalidomide) In Patients With ...
-
A Study Of CC-5013 Plus Dexamethasone Versus ... - Clinical Trials
-
Definition Of CC-5013 - NCI Dictionary Of Cancer Terms
-
Immunomodulatory Drug CC-5013 Overcomes Drug Resistance And ...
-
Lenalidomide (CC-5013) | ≥99%(HPLC) | E3 Ligase Ligand Chemical
-
EU Clinical Trials Register
-
Phase III Intergroup Study Of Lenalidomide (CC-5013) Versus ...
-
Lenalidomide (CC-5013) | Immunomodulator - MedChemExpress
-
Lenalidomide: An Immunomodulatory Drug | Future Oncology
-
Multiple-dose Pharmacokinetics And Safety Of CC-5013 In 15 ...
-
Phase I Study To Determine The Safety, Tolerability And ... - Nature
-
Clinical Trial On Multiple Myeloma: CC-5013, Lenalidomide - ICH GCP
-
Preliminary Results Of A Phase II Study Of CC-5013 (Lenalidomide ...
-
Lenalidomide (CC-5013) | CALIBRE SCIENTIFIC